3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Conditions
Vascular Calcification
1
Neoplasm Metastasis
1
Kidney Diseases
1
Hyperparathyroidism
1
Chronic Kidney Disease-Mineral and Bone Disorder
1
Bone Diseases
1
Interventions
Cisplatin
263
Radiotherapy
166
Cetuximab
159
Docetaxel
105
Fluorouracil
104
pembrolizumab
94
Radiotherapy, Intensity-Modulated
83
Carboplatin
80
Paclitaxel
73
Nivolumab
59
Erlotinib Hydrochloride
35
Surveys and Questionnaires
32
Gemcitabine
32
durvalumab
30
Radiation
29
Drug Therapy
25
Immunohistochemistry
21
Gefitinib
21
Capecitabine
21
tremelimumab
18
Bevacizumab
18
Surgical Procedures, Operative
17
Sorafenib
17
Magnetic Resonance Spectroscopy
17
Ipilimumab
17
Pemetrexed
16
lenvatinib
15
atezolizumab
15
Radiosurgery
15
Gene Expression Profiling
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
etelcalcetide hydrochloride
×
Head & Neck
×
Clear all
NCT03960437
2023-09-21
Parsabiv-MBD
Columbia University
Phase 2
Completed
22 enrolled
14 charts